These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12127525)

  • 21. Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Fattori R; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2002 Jan; 12(1):5-8. PubMed ID: 11738561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.
    Regan J; Bruno J; McGarry D; Poli G; Hanney B; Bower S; Travis J; Sweeney D; Miller B; Souness J; Djuric S
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2737-42. PubMed ID: 9873613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.
    Huai Q; Sun Y; Wang H; Macdonald D; Aspiotis R; Robinson H; Huang Z; Ke H
    J Med Chem; 2006 Mar; 49(6):1867-73. PubMed ID: 16539372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
    Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Hatzelmann A; Van Klink GP; Van der Laan IJ; Sterk GJ; Thibaut U; Ulrich WR; Timmerman H
    J Med Chem; 2001 Aug; 44(16):2523-35. PubMed ID: 11472206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
    Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
    J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
    Wu Y; Zhou Q; Zhang T; Li Z; Chen YP; Zhang P; Yu YF; Geng H; Tian YJ; Zhang C; Wang Y; Chen JW; Chen Y; Luo HB
    J Med Chem; 2019 Apr; 62(8):4218-4224. PubMed ID: 30916555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
    Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aryl sulfonamides as selective PDE4 inhibitors.
    Montana JG; Buckley GM; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Miotla J; Naylor RJ; Runcie KA; Tuladhar B; Warneck JB
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2635-40. PubMed ID: 9873594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Highly potent PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kusumi K; Kato M; Kohno H; Odagaki Y; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Bioorg Med Chem; 2004 Sep; 12(17):4645-65. PubMed ID: 15358291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
    Alexander RP; Warrellow GJ; Eaton MA; Boyd EC; Head JC; Porter JR; Brown JA; Reuberson JT; Hutchinson B; Turner P; Boyce B; Barnes D; Mason B; Cannell A; Taylor RJ; Zomaya A; Millican A; Leonard J; Morphy R; Wales M; Perry M; Allen RA; Gozzard N; Hughes B; Higgs G
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1451-6. PubMed ID: 12031318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
    Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
    J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
    Ashton MJ; Cook DC; Fenton G; Karlsson JA; Palfreyman MN; Raeburn D; Ratcliffe AJ; Souness JE; Thurairatnam S; Vicker N
    J Med Chem; 1994 May; 37(11):1696-703. PubMed ID: 8201604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.
    Charpiot B; Brun J; Donze I; Naef R; Stefani M; Mueller T
    Bioorg Med Chem Lett; 1998 Oct; 8(20):2891-6. PubMed ID: 9873643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.
    Hulme C; Moriarty K; Miller B; Mathew R; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Huang FC; Labaudiniere R; Djuric SW
    Bioorg Med Chem Lett; 1998 Jul; 8(14):1867-72. PubMed ID: 9873449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
    J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
    [No Abstract]   [Full Text] [Related]  

  • 37. Cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of (R)- and (S)-isomer of 7-methyl- or 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]- purin-5-one.
    Suzuki H; Nomura M; Miyamoto K; Sawanishi H; Yamamoto K
    Biol Pharm Bull; 2004 Mar; 27(3):357-60. PubMed ID: 14993802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 8-Methoxyquinolines as PDE4 inhibitors.
    Billah M; Buckley GM; Cooper N; Dyke HJ; Egan R; Ganguly A; Gowers L; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Oxford J; Peake JC; Picken CL; Piwinski JJ; Naylor R; Sabin V; Shih NY; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1617-9. PubMed ID: 12039575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of some phosphodiesterase inhibitors on two different preparations of adenosine 3',5'-monophosphate phosphodiesterase.
    Du Moulin A; Schultz J
    Experientia; 1975 Aug; 31(8):883-4. PubMed ID: 169139
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.